Fig. 5.

Biomarker results based on PFS. Genomic events based on the timing of progression following treatment (PFS > 12 vs. ≤12 months). Kaplan–Meier estimates of PFS in 22 patients by specific somatic mutations. Frameshift variant of STAG2 and missense variant of TRAF7 occurred in the same sample from the same patient, which generated the same survival curve. Similarly, the missense variant of DMD, missense variant of SPINK1, CUX1-AUTS2 fusion, and VEGFA amplification occurred in the same sample from the same patient, which generated the same survival curve. Genes significantly associated with PFS were highlighted in red. Presented P values were log-rank, and two-sided P values < 0.05 were considered statistically significant. Abbreviations: PFS, progression-free survival; RATC, response after two cycles; OS, overall survival; TMB, Tumor Mutation Burden; CR, complete response; PR, partial response; SD, stable disease; PD, disease progression.